The Curator finds, summarizes, and links to the highest-quality, most authoritative online sources of business and political news and information: breaking news, analysis, background and opinion. Learn more »
Have something you'd like to share?
Is there an important story you think we should cover or features you would like added? Let us know »
Genentech and Biogen Idec’s co-marketed drug Rituxan “significantly” boosted progression-free survival for patients with chronic lymphocytic leukemia when used in combination with two chemotherapy drugs. (FiercePharma)
Categories: Biotech, Pharma
No Comments Yet
You can be the first to comment!
Leave a comment